427 related articles for article (PubMed ID: 33389441)
1. The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico.
Elfiky AA; Azzam EB; Shafaa MW
Mol Divers; 2022 Feb; 26(1):171-181. PubMed ID: 33389441
[TBL] [Abstract][Full Text] [Related]
2. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J
Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223
[TBL] [Abstract][Full Text] [Related]
3. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
Elfiky AA
Life Sci; 2020 May; 248():117477. PubMed ID: 32119961
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an
Elfiky AA
J Biomol Struct Dyn; 2021 Jun; 39(9):3204-3212. PubMed ID: 32338164
[TBL] [Abstract][Full Text] [Related]
5. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.
Elfiky AA
Life Sci; 2020 Jul; 253():117592. PubMed ID: 32222463
[TBL] [Abstract][Full Text] [Related]
6. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.
Wakchaure PD; Ghosh S; Ganguly B
J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase.
Zhang L; Zhou R
J Phys Chem B; 2020 Aug; 124(32):6955-6962. PubMed ID: 32521159
[TBL] [Abstract][Full Text] [Related]
8. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
Shannon A; Le NT; Selisko B; Eydoux C; Alvarez K; Guillemot JC; Decroly E; Peersen O; Ferron F; Canard B
Antiviral Res; 2020 Jun; 178():104793. PubMed ID: 32283108
[TBL] [Abstract][Full Text] [Related]
9. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
[TBL] [Abstract][Full Text] [Related]
10. BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir.
Tang W-F; Chang Y-H; Lin C-C; Jheng J-R; Hsieh C-F; Chin Y-F; Chang T-Y; Lee J-C; Liang P-H; Lin C-Y; Lin G-H; Cai J-Y; Chen Y-L; Chen Y-S; Tsai S-K; Liu P-C; Yang C-M; Shadbahr T; Tang J; Hsu Y-L; Huang C-H; Wang L-Y; Chen CC; Kau J-H; Hung Y-J; Lee H-Y; Wang W-C; Tsai H-P; Horng J-T
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0095623. PubMed ID: 38446062
[TBL] [Abstract][Full Text] [Related]
11. Structural Homology-Based Drug Repurposing Approach for Targeting NSP12 SARS-CoV-2.
Aljuaid A; Salam A; Almehmadi M; Baammi S; Alshabrmi FM; Allahyani M; Al-Zaydi KM; Izmirly AM; Almaghrabi S; Baothman BK; Shahab M
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431833
[TBL] [Abstract][Full Text] [Related]
12. Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective.
Sonousi A; Mahran HA; Ibrahim IM; Ibrahim MN; Elfiky AA; Elshemey WM
Pharmacol Rep; 2021 Dec; 73(6):1754-1764. PubMed ID: 34165771
[TBL] [Abstract][Full Text] [Related]
13. Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity.
Tsuji M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232311
[TBL] [Abstract][Full Text] [Related]
14. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
15. Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp).
Karthic A; Kesarwani V; Singh RK; Yadav PK; Chaturvedi N; Chauhan P; Yadav BS; Kushwaha SK
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164069
[TBL] [Abstract][Full Text] [Related]
16. Novel sofosbuvir derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective.
Alrehaily A; Elfiky AA; Ibrahim IM; Ibrahim MN; Sonousi A
Sci Rep; 2023 Dec; 13(1):23080. PubMed ID: 38155165
[TBL] [Abstract][Full Text] [Related]
17. Impact of Remdesivir Incorporation along the Primer Strand on SARS-CoV-2 RNA-Dependent RNA Polymerase.
Naseem-Khan S; Berger MB; Leddin EM; Maghsoud Y; Cisneros GA
J Chem Inf Model; 2022 May; 62(10):2456-2465. PubMed ID: 35435671
[TBL] [Abstract][Full Text] [Related]
18. Theaflavin-3'-O-gallate a Black-tea Constituent Blocked SARS CoV-2 RNA dependant RNA Polymerase Active-site with Better Docking Results than Remdesivir.
Banerjee A; Kanwar M; Maiti S
Drug Res (Stuttg); 2021 Oct; 71(8):462-472. PubMed ID: 34517419
[TBL] [Abstract][Full Text] [Related]
19. Remdesivir MD Simulations Suggest a More Favourable Binding to SARS-CoV-2 RNA Dependent RNA Polymerase Mutant P323L Than Wild-Type.
Mohammad A; Al-Mulla F; Wei DQ; Abubaker J
Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34206274
[TBL] [Abstract][Full Text] [Related]
20. Remdesivir Strongly Binds to Both RNA-Dependent RNA Polymerase and Main Protease of SARS-CoV-2: Evidence from Molecular Simulations.
Nguyen HL; Thai NQ; Truong DT; Li MS
J Phys Chem B; 2020 Dec; 124(50):11337-11348. PubMed ID: 33264025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]